TheraRadar
Clinical-Stage Companies / Onconic

Onconic

Pre-Approval PRO BETA
16
Total Trials
4
Phase 3
5
Phase 2
4
Recruiting
147
Score

Pipeline by Phase

Phase 3
4
Phase 2
5
Phase 1
9

Therapeutic Focus

Healthy Ovarian Cancer Pancreatic Ductal Adenocarcinoma Gastric Cancer (GC) Drug Drug Interaction (DDI)

Clinical Trials (16)

NCT06439563 Phase 3 RECRUITING

Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers

Started: 10/22/2024

NCT07160790 Phase 3 NOT YET RECRUITING

Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease

Started: 9/2/2025

NCT05443984 Phase 3 COMPLETED

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

Started: 1/17/2022

NCT05448001 Phase 3 COMPLETED

Clinical Trial to Evaluate the Efficacy and Safety of JP-1366 in Patients With Gastric Ulcer

Started: 9/19/2022

NCT07370818 Phase 2 NOT YET RECRUITING

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

Started: 2/27/2026

NCT05475184 Phase 2 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of JPI-547 in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor

Started: 8/31/2022

NCT04282954 Phase 2 COMPLETED

Clinical Trial to Evaluate the Safety and Efficacy of JP-1366 in Patients With Erosive Gastroesophageal Reflux Disease

Started: 11/15/2019

NCT05257993 Phase 1 RECRUITING

Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer

Started: 3/30/2022

NCT07265466 Phase 1 RECRUITING

to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban

Started: 11/17/2025

NCT07364422 Phase 1 NOT YET RECRUITING

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Started: 2/27/2026

NCT07181538 Phase 1 COMPLETED

Phase 1 Study of JLP-2302 and JP-1366: PK and Safety in Healthy Volunteers

Started: 2/4/2025

NCT05712681 Phase 1 COMPLETED

Clinical Trial to Evaluate Food-Effects on Pharmacokinetics and Pharmacodynamics of Oral Single Dose of JP-1366 Tablet in Healthy Volunteers

Started: 3/29/2023

NCT05814809 Phase 1 COMPLETED

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

Started: 9/30/2022

NCT05181124 Phase 1 COMPLETED

Compare Pharmacokinetics and Safety of JP-1366 Between Korean and Caucasian

Started: 3/5/2021

NCT04335604 Phase 1 COMPLETED

A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors

Started: 12/6/2017

NCT05194046 Phase 1 COMPLETED

Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers

Started: 11/18/2020

Drug Candidates

JPI-547 modified FOLFIRINOX Gemcitabine-nab-paclitaxel Bevacizumab Irinotecan (drug) JP-1366 and clopidogrel JP-1366 and aspirin JP-1366 and atorvastatin JP-1366 and apixaban JLP-2302
Activity Status: Active
Last Trial Started: 2/27/2026
Last Trial Ended: 3/5/2025
Trials (12 months): 4
Completed Trials: 9
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.